CORCEPT THERAPEUTICS INC (CORT)       24.32  -0.15 (-0.61%)

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 238 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The company has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.

Company Info

CORCEPT THERAPEUTICS INC

149 Commonwealth Dr

Menlo Park CALIFORNIA 94025

P: 16506888803.0

CEO: Joseph K. Belanoff

Employees: 238

Website: https://www.corcept.com/